Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline
Top Cited Papers
- 20 April 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (12), 1596-1605
- https://doi.org/10.1200/jco.2006.10.1949
Abstract
Purpose To update the 2004 American Society of Clinical Oncology (ASCO) guideline on initial hormonal management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer (PCa). Methods The writing committee based its recommendations on an updated systematic literature review. Recommendations were approved by the Expert Panel, the ASCO Health Services Committee, and the ASCO Board of Directors. Results Seven randomized controlled trials (four new), one systematic review, one meta-analysis (new), one Markov model, and one delta-method 95% CI procedure for active controlled trials (new) informed the guideline update. Recommendations Bilateral orchiectomy or luteinizing hormone–releasing hormone agonists are recommended initial androgen-deprivation treatments (ADTs). Nonsteroidal antiandrogen monotherapy merits discussion as an alternative; steroidal antiandrogen monotherapy should not be offered. Combined androgen blockade should be considered. In metastatic or progressive PCa, immediate versus symptom-onset institution of ADT results in a moderate decrease (17%) in relative risk (RR) for PCa-specific mortality, a moderate increase (15%) in RR for non–PCa-specific mortality, and no overall survival advantage. Therefore, the Panel cannot make a strong recommendation for early ADT initiation. Prostate-specific antigen (PSA) kinetics and other metrics allow identification of populations at high risk for PCa-specific and overall mortality. Further studies must be completed to assess whether patients with adverse prognostic factors gain a survival advantage from immediate ADT. For patients electing to wait until symptoms for ADT, regular monitoring visits are indicated. For patients with recurrence, clinical trials should be considered if available. Currently, data are insufficient to support use of intermittent androgen blockade outside clinical trials.Keywords
This publication has 25 references indexed in Scilit:
- Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891Journal of Clinical Oncology, 2006
- Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerBJU International, 2006
- EARLY VERSUS DELAYED ENDOCRINE TREATMENT OF pN1-3 M0 PROSTATE CANCER WITHOUT LOCAL TREATMENT OF THE PRIMARY TUMOR: RESULTS OF EUROPEAN ORGANISATION FOR THE RESEARCH AND TREATMENT OF CANCER 30846—A PHASE III STUDYJournal of Urology, 2004
- Timing and choice of androgen ablationProstate Cancer and Prostatic Diseases, 2004
- Docetaxel/gemcitabine followed by gemcitabine and radiotherapy in patients with pancreatic adenocarcinomaJournal of Clinical Oncology, 2004
- American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate CancerJournal of Clinical Oncology, 2004
- A re‐assessment of the role of combined androgen blockade for advanced prostate cancerBJU International, 2004
- Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.Japanese Journal of Clinical Oncology, 2004
- Design and analysis of non‐inferiority mortality trials in oncologyStatistics in Medicine, 2002
- Intermittent Versus Continuous Total Androgen Blockade in the Treatment of Patients with Advanced Hormone-Naive Prostate Cancer: Results of a Prospective Randomized Multicenter TrialClinical Prostate Cancer, 2002